Skip to main content

Deposition Taken for Breast Implants Case Sheds Light on Allergan’s Inner Workings

An important deposition was recently taken in the Allergan textured breast implant national litigation, reported Levin Papantonio Rafferty (LPR) Attorney Virginia Buchanan. The deposition provided meaningful insight into the inner workings of Allergan in its design, manufacture, and sale of BioCELL textured breast implant products.

“Allergan and its predecessor companies have a history spanning over 30 years, and numerous individuals have held key roles in the corporate hierarchy along the way,” Buchanan said. “By identifying key people in the deposition process, the victims and their lawyers can focus their attention on obtaining critical evidence from those key people.”

LPR represents many clients in the Allergan breast implant litigation, including families of victims who have died from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

Senior partner Virginia Buchanan is co-lead counsel in the national multi-district litigation. LPR associate Becca Timmons is on the class certification committee. “The LPR team played an important role in the undertaking of this important deposition,” Buchanan said.

More on Allergan Breast Implants and BIA-ALCL

Reports of BIA-ALCL are particularly high in patients who have textured breast implants. The disease is not breast cancer, but rather a form of non-Hodgkin’s lymphoma. It results from T-cells’ excessive production of a specific protein due to gene mutation.

The U.S. Food and Drug Administration (FDA) requested a recall of Allergan’s textured breast implants in 2019 after reviewing adverse event reports involving BIA-ALCL. “The risk of BIA-ALCL with Allergan BIOCELL textured implants is approximately 6 times the risk of BIA-ALCL with textured implants from other manufacturers marketing in the U.S.,” the agency stated, adding that “continued distribution of Allergan’s BIOCELL textured breast implants would likely cause serious, adverse health consequences and potentially death from BIA-ALCL.”